New paper out in Cell Chemical Biology!

We are thrilled to share a story emerging from our androgen receptor program is now available for download at Cell Chemical Biology!

This work, co-led by Dr. Andre Richters and Dr. Shelby Doyle, has been a long-running effort from our team focused on prostate cancer, who discovered KI-ARv-03, a selective CDK9 inhibitor with potent activity in castration resistant prostate cancer models. The initial discovery was supported through a partnership with Janssen Pharmaceuticals and validated in collaboration with the lab of Dr. Steven Balk through the Koch Institute and Dana-Farber/Harvard Cancer Center (DF/HCC) Bridge Project. More recently this project grew to collaborative effort between our lab, colleagues at the Therapeutic Innovation Center at Baylor College of Medicine, and Kronos Bio, Inc., who optimized KI-ARv-03 to produce KB-0742.

We are grateful to the entire team of authors and extend congratulations to all!

REFERENCE: *André Richters, *Shelby K. Doyle, David B. Freeman, Christina Lee, Becky S. Leifer, Sajjeev Jagannathan, Florian Kabinger, Jošt Vrabič Koren, Nicholas B. Struntz, Julie Urgiles, Ryan A. Stagg, Brice H. Curtin, Deep Chatterjee, Sebastian Mathea, Peter J. Mikochik, Tamara D. Hopkins, Hua Gao, Jonathan Branch, Hong Xin, Lori Westover, Gilles C. Bignan, Brent A. Rupnow, Kristen L. Karlin, Calla M. Olson, Thomas F. Westbrook, Joseph Vacca, Chris M. Wilfong, B. Wesley Trotter, Douglas C. Saffran, Norbert Bischofberger, Stefan Knapp, Joshua W. Russo, Ian Hickson, James R. Bischoff, Marco M. Gottardis, Steven P. Balk, Charles Y. Lin, Marius S. Pop, Angela N. Koehler. “Modulating Androgen Receptor-Driven Transcription in Prostate Cancer with Selective CDK9 Inhibitors.” Cell Chemical Biology. Open Access Published: October 20, 2020 DOI:https://doi.org/10.1016/j.chembiol.2020.10.001